INDOCO258.00

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,381 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation91.9113.8126.5
+ Finance Costs37.766.2122.3
+ Interest Income-4.0-0.8-1.4
+ Share-based Payments2.92.20.7
+ Unrealised FX (Gain) / Loss0.41.6-8.6
+ Other Non-cash Items0.4-0.20.6
+ Other Reconciling Items8.30.89.3
Changes in Working Capital
+ Inventories-27.1-66.314.1
+ Trade Receivables — Current-63.850.7-137.4
+ Other Financial Assets — Current-4.81.8-10.9
+ Other Financial Assets — Non-current-5.5-0.0-0.5
+ Other Current Assets-40.4-33.8-16.1
+ Other Non-current Assets-3.7-0.5-14.4
+ Trade Payables — Current30.154.6105.0
+ Other Financial Liabilities — Current28.8-8.729.4
+ Other Financial Liabilities — Non-current5.13.547.8
+ Other Current Liabilities-5.18.735.1
+ Provisions — Current-1.2-3.21.7
+ Provisions — Non-current0.3-3.91.7
Cash from Operating Activities
Profit Before Tax (per I/S)135.8-74.4-106.57.9
+ Total Adjustments (incl. Working Capital)50.4186.4304.9
Cash from Operations (pre-tax)186.2112.1198.4
+ Income Taxes Paid29.517.16.2
Cash from Operating Activities156.794.9192.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)427.3356.2147.5
+ Disp of Fixed Assets1.73.846.6
+ Purchase of Investments (Equity / Debt)6.20.00.0
+ Sale of Investments (Equity / Debt)0.07.90.0
+ Interest Received — Investing4.50.81.4
+ Other Inflows / (Outflows) — Investing-6.44.5-2.1
Cash from Investing Activities-433.8-339.1-101.6
Cash from Financing Activities
+ Proceeds from Other Equity Instruments0.81.61.3
+ Proceeds from Borrowings251.1264.3146.5
+ Repayment of Borrowings-89.2-58.688.7
+ Payment of Lease Liabilities0.05.211.0
+ Payment of Finance Lease Liabilities3.8
+ Interest Paid36.163.9122.7
+ Dividends Paid20.713.91.9
+ Other Inflows / (Outflows) — Financing0.00.0-0.4
Cash from Financing Activities280.4241.4-76.8
Net Changes in Cash (pre-FX)3.3-2.813.8
Net Changes in Cash3.3-2.813.8
Closing Cash14.9
Reference Items
EBITDA244.399.3141.8165.3
EBITDA Margin %13.445.967.688.82
Free Cash Flow (CFO − Capex)-270.6-261.244.744.7
Free Cash Flow to Equity-3.5-35.7
Free Cash Flow per Basic Share-29.32-28.304.844.84
Price to Free Cash Flow53.27
Cash Flow to Net Income1.62-1.22-1.95
Cash Paid for Taxes29.517.16.2
Cash Paid for Interest36.163.9122.7
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.